As the population of adults with congenital heart disease (ACHD) continues to grow, a significant and often underrecognized complication is the development of cardiorenal syndrome (CRS)—a complex, bidirectional interaction between cardiac and renal dysfunction. While CRS has been extensively studied in acquired heart failure, its manifestations and implications in ACHD remain insufficiently understood. Emerging data suggest that renal dysfunction is highly prevalent in ACHD, with significant associations to adverse outcomes regardless of cardiac lesion type or functional status. This review explores CRS within three key physiologic categories in ACHD: patients with a systemic right ventricle, those with a subpulmonary right ventricle, and those with Fontan circulation. Each subgroup presents unique hemodynamic challenges that affect renal perfusion, filtration pressure, and systemic congestion, contributing to both acute and chronic renal impairment. The utility of renal biomarkers such as albuminuria, cystatin C, and estimated glomerular filtration rate (eGFR) is emphasized, alongside the importance of early detection and multidisciplinary management. Heart failure therapy tailored to congenital anatomy, neurohormonal modulation, and careful volume control remain the cornerstones of treatment, while transplantation strategies must consider the potential for irreversible end-organ damage. Given the profound implications of CRS on quality of life and survival, a comprehensive understanding of its pathophysiology and management in ACHD is critical to optimizing long-term outcomes in this increasingly complex patient population.
Background/Objectives: Adults with congenital heart disease (ACHD) are at high risk for late cardiac sequelae and hypertension (HTN). Ambulatory blood pressure monitoring (ABPM) is superior to office measurements in reproducibility, association with cardiovascular outcomes, and detection of masked and white coat HTN (WCH). The utility of ABPM in the ACHD population is not well studied. This study aims to determine the prevalence of hypertension in the ACHD population and evaluate the utility of ABPM in diagnosing hypertension in the ACHD population. Methods: This is a single-center retrospective analysis of ACHD patients who completed ABPM from 2021 to 2024. Results: Forty ACHD patients underwent ABPM during the study period. Twenty-nine (73%) had hypertension (HTN) in clinic. On ABPM, nine (23%) were confirmed normotensive, 15 (38%) had white coat hypertension (WCH), 14 (35%) were confirmed hypertensive, and two (5%) had masked HTN. There was a 33% decrease in patients meeting criteria for HTN on ABPM compared to in clinic (p = 0.002). Ten patients with HTN on ABPM had follow-up, during which seven (70%) had improved clinic blood pressure. One patient (2.5%) had an antihypertensive removed following WCH diagnosis on ABPM. Conclusions: ABPM is a useful way to diagnose and monitor hypertension in the ACHD population. Based on ABPM, many patients (43%) were found to have either WCH or masked HTN, and 15% had their HTN stage reclassified. ABPM results led to 33% of patients having subsequent medication adjustment. Data from ABPM can help optimize medical management, in turn reducing cardiac strain and acquired heart disease risk in ACHD patients.